Cecropin A Evidence Guide
Evidence for Cecropin A is too preliminary to support a research protocol with confidence. This insect-derived antimicrobial peptide has no human data, no therapeutic trials, and limited relevance to human therapeutic development beyond serving as a template for synthetic antimicrobial peptide design.
Our Take
Evidence for Cecropin A is too preliminary to support a research protocol with confidence. This insect-derived antimicrobial peptide has no human data, no therapeutic trials, and limited relevance to human therapeutic development beyond serving as a template for synthetic antimicrobial peptide design.
- Best for
- Antimicrobial peptide scaffold research, synthetic AMP design reference
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol
Benefits and Evidence
- Gram-Negative Antibacterial Activity: Level D, mostly non-human evidence - Potent bactericidal activity against E. coli, Pseudomonas aeruginosa, Klebsiella, and other gram-negative pathogens demonstrated across numerous in vitro studies.
- Anti-Cancer Activity: Level D, mostly non-human evidence - Mader et al. (2005, Exp Cell Res) demonstrated that bovine lactoferricin (LfcinB, 25-residue derivative) selectively killed MDA-MB-435 breast cancer and neuroblastoma cells at 25-50 ug/mL while sparing normal fibroblasts, attributed to the higher anionic phosphatidylserine content of tumor membranes.
Side Effects and Warnings
- No human clinical data available
- Low mammalian cell toxicity in vitro at bactericidal concentrations
- Potential hemolytic activity at very high concentrations
- Not available for clinical or therapeutic use
- Rapidly degraded by mammalian proteases, limiting in vivo utility
- Synthetic analogs are being developed to improve stability
- No human safety data exists
Research Dosage References
- <strong>In vitro</strong> - 0.5-10 mcg/mL (MIC range) - N/A - Studied exclusively in laboratory settings. Minimum inhibitory concentrations vary by bacterial species.
Mechanism of Action
Cecropin A destroys bacteria through a sequential process: 1. Electrostatic binding: Cationic residues are attracted to the negatively charged outer leaflet of bacterial membranes (LPS in gram-negatives). 2. Alpha-helix insertion: The amphipathic alpha-helical structure inserts into the lipid bilayer, creating transient pores and disrupting membrane integrity. 3. Carpet model disruption: At higher concentrations, peptide molecules carpet the membrane surface, causing detergent-like solubilization of the lipid bilayer. 4. Selective toxicity: Preferentially targets bacterial membranes rich in phosphatidylglycerol and cardiolipin over cholesterol-containing mammalian membranes.
Legal Status
Cecropin A is a research reagent available from biochemical suppliers. Not approved for therapeutic use in any country. Used exclusively for research and as a template for antimicrobial peptide drug design.